JP2022501383A5 - - Google Patents
Info
- Publication number
- JP2022501383A5 JP2022501383A5 JP2021515616A JP2021515616A JP2022501383A5 JP 2022501383 A5 JP2022501383 A5 JP 2022501383A5 JP 2021515616 A JP2021515616 A JP 2021515616A JP 2021515616 A JP2021515616 A JP 2021515616A JP 2022501383 A5 JP2022501383 A5 JP 2022501383A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- composition according
- prostate cancer
- contrast agent
- metastatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023204832A JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862734690P | 2018-09-21 | 2018-09-21 | |
| US62/734,690 | 2018-09-21 | ||
| PCT/US2019/051903 WO2020061293A1 (en) | 2018-09-21 | 2019-09-19 | Shielding agents and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204832A Division JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501383A JP2022501383A (ja) | 2022-01-06 |
| JP2022501383A5 true JP2022501383A5 (https=) | 2022-09-29 |
| JP7429688B2 JP7429688B2 (ja) | 2024-02-08 |
Family
ID=69887812
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021515616A Active JP7429688B2 (ja) | 2018-09-21 | 2019-09-19 | シールド剤およびそれらの使用 |
| JP2023204832A Active JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023204832A Active JP7748438B2 (ja) | 2018-09-21 | 2023-12-04 | シールド剤およびそれらの使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20210323985A1 (https=) |
| EP (1) | EP3853213A4 (https=) |
| JP (2) | JP7429688B2 (https=) |
| CN (1) | CN113166087B (https=) |
| WO (1) | WO2020061293A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201590783A1 (ru) * | 2012-11-15 | 2015-11-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma |
| EP3533473A3 (en) | 2013-11-14 | 2019-12-18 | Endocyte, Inc. | Compounds for positron emission tomography |
| CN112368024A (zh) | 2018-04-17 | 2021-02-12 | 恩多塞特公司 | 治疗癌症的方法 |
| CN114096264B (zh) | 2019-05-20 | 2025-03-14 | 因多塞特股份有限公司 | 制备psma缀合物的方法 |
| US20250332265A1 (en) * | 2021-11-09 | 2025-10-30 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2097111B1 (en) | 2006-11-08 | 2015-07-15 | Molecular Insight Pharmaceuticals, Inc. | Heterodimers of glutamic acid |
| PL2187965T3 (pl) | 2007-08-17 | 2020-05-18 | Purdue Research Foundation | Koniugaty wiążący psma ligand-łącznik i sposoby ich zastosowania |
| WO2012174136A1 (en) * | 2011-06-15 | 2012-12-20 | Cancer Targeted Technology Llc | Chelated psma inhibitors |
| EA201590783A1 (ru) * | 2012-11-15 | 2015-11-30 | Эндосайт, Инк. | Конъюгаты для доставки лекарственных средств и способы лечения заболеваний, вызванных клетками, экспрессирующими psma |
| EP3456700A1 (en) | 2013-10-18 | 2019-03-20 | Deutsches Krebsforschungszentrum | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
| PL3177632T3 (pl) | 2014-08-06 | 2022-06-13 | The Johns Hopkins University | Proleki inhibitora antygenu błony swoistego dla stercza (PSMA) |
| JP2017530109A (ja) | 2014-09-08 | 2017-10-12 | モレキュラ インサイト ファーマシューティカルズ インコーポレイテッド | 前立腺癌についてのｐｓｍａを標的とした放射性核種治療中の臓器の保護 |
| AU2018250609B2 (en) * | 2017-04-11 | 2024-05-09 | Adarga, Llc | Prodrugs of 2-PMPA for healthy tissue protection during PSMA-targeted cancer imaging or radiotherapy |
-
2019
- 2019-09-19 EP EP19863710.0A patent/EP3853213A4/en active Pending
- 2019-09-19 CN CN201980076992.7A patent/CN113166087B/zh active Active
- 2019-09-19 US US17/277,806 patent/US20210323985A1/en active Pending
- 2019-09-19 JP JP2021515616A patent/JP7429688B2/ja active Active
- 2019-09-19 WO PCT/US2019/051903 patent/WO2020061293A1/en not_active Ceased
-
2023
- 2023-12-04 JP JP2023204832A patent/JP7748438B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022501383A5 (https=) | ||
| Meredith et al. | Phase II study of interferon-enhanced 131I-labeled high affinity CC49 monoclonal antibody therapy in patients with metastatic prostate cancer | |
| JP2020033360A5 (https=) | ||
| CN102171187A (zh) | Psma-结合剂及其用途 | |
| Scott et al. | A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen | |
| JP2021522193A5 (https=) | ||
| JP2020531463A5 (https=) | ||
| Pfestroff et al. | Current status and future perspectives of PSMA-targeted therapy in Europe: opportunity knocks | |
| JP2019527740A5 (https=) | ||
| Illidge et al. | Radioimmunotherapy in follicular lymphoma | |
| Shinto et al. | Clinical utility of 188Rhenium-hydroxyethylidene-1, 1-diphosphonate as a bone pain palliative in multiple malignancies | |
| JP2024516359A5 (https=) | ||
| Du et al. | Preliminary evaluation of alpha-emitting radioembolization in animal models of hepatocellular carcinoma | |
| Dormehl et al. | Biodistribution and pharmacokinetics of variously sized molecular radiolabelled polyethyleneiminomethyl phosphonic acid as a selective bone seeker for therapy in the normal primate model | |
| JP2006523664A5 (https=) | ||
| Kim et al. | Preclinical evaluation of isostructural Tc-99m-and Re-188-folate-Gly-Gly-Cys-Glu for folate receptor-positive tumor targeting | |
| JP2008533079A5 (https=) | ||
| Dallagi et al. | Synthesis and Biodistribution of 1-[2-(cyclopentadienyltricarbonyltechnetium-99m)-2-oxo-ethoxy-phenyl]-1, 2-di-(p-hydroxyphenyl) but-1-ene for tumor imaging | |
| JP7239662B2 (ja) | 複合体、造影剤、及びｃｘｃｒ４関連疾患を治療又は診断するための医薬品 | |
| JP2025503096A5 (https=) | ||
| Skóra et al. | Effectiveness of radioisotope therapy in bone metastases, based on personal experience | |
| JP2003512296A (ja) | がんの治療における放射性シスプラチン | |
| Shinto et al. | Important clinical applications of 188Rhenium for radionuclide therapy | |
| JP2024520307A5 (https=) | ||
| JP2024522163A5 (https=) |